GO
Loading...

Latest Business News Wires - Business Headlines

More

  • *$139 billion in dry powder in Asia, $130 bln new funds being raised-Preqin. HONG KONG, Oct 25- The public appearance of Henry Kravis at KKR's new Singapore office underscores the private equity industry's growing interest in Southeast Asia, at a time when regional funds are growing and deal volumes are falling.

  • *Yuan hits all time record high in morning trade. Oct 25- China's yuan touched its strongest ever level on Thursday and crept within a whisker of its strong-side limit, as dealers said short covering added to strong corporate demand for yuan. The People's Bank of China set its midpoint at 6.3047 on Thursday, moderately stronger than Wednesday's fix.

  • Passengers bump up Q3 profits for Norwegian Thursday, 25 Oct 2012 | 4:46 AM ET

    OSLO, Norway-- Norwegian Air Shuttle, one of Europe's fastest-growing airlines, has posted a 27 percent increase in third-quarter net profits on the back of a significant increase of passengers. Thursday's report showed the company made a net profit of 628 million kroner, up sharply from the 495 million kroner recorded in the same three months a year ago.

  • ECB: Lending still weak in slack eurozone economy Thursday, 25 Oct 2012 | 4:43 AM ET

    FRANKFURT, German-- Another drop in lending to companies in the 17- country eurozone showed the economic downturn is deepening, as a brighter mood on financial markets fails to catch on with businesses.

  • UK recession over as economy grows 1 pct in Q3 Thursday, 25 Oct 2012 | 4:43 AM ET

    LONDON-- Britain's economy emerged from its nine-month recession in the July to September quarter, when spending on the Olympics helped it grow by a bigger than expected 1 percent, according to official figures released Thursday.

  • Novartis defends flu drugs, posts flat Q3 profits Thursday, 25 Oct 2012 | 4:34 AM ET

    GENEVA-- Swiss pharmaceutical giant Novartis AG defended a range of flu drugs that have been banned in Italy, while posting virtually flat third quarter profits as new drugs offset patent expirations. On Wednesday, Italy's health ministry banned the sale of four Novartis flu drugs for possible side-effects.

  • WPP: Ads income from Olympics, US elex disappoints Thursday, 25 Oct 2012 | 4:29 AM ET

    LONDON-- WPP PLC, the world's largest advertising group, has lowered its full-year outlook after not doing as well as expected from the Olympics, the U.S. presidential campaign and the European soccer championships.

  • BEIJING, Oct 25- China's factory output should grow faster in the last three months of 2012 than in the third quarter, though the recovery remains clouded by uncertainty in export markets, the Ministry of Industry and Information Technology said on Thursday.

  • FOREX-Yen weighed down by BOJ easing hopes; kiwi rises Thursday, 25 Oct 2012 | 4:19 AM ET

    SINGAPORE, Oct 25- The dollar edged higher versus the yen on Thursday as the yen stayed under pressure on expectations for more Bank of Japan monetary easing, while a less-dovish-than-expected New Zealand central bank gave the kiwi dollar a boost.

  • SINGAPORE, Oct 25- Brent futures rose above $108 on Thursday as positive economic data out of the world's top oil consumer, the United States, revived hopes of a recovery in demand growth, although a worsening outlook for Europe capped gains.

  • ADVISORY-UBS Singapore trader story withdrawn Thursday, 25 Oct 2012 | 4:00 AM ET

    Please be advised that a story saying UBS AG has suspended at least one trader in Singapore for possible manipulation of interbank lending rates is wrong and is withdrawn. The trader, Prakant Sood, said that he is still employed by the bank and has never been involved in U.S. dollar Libor trading, or trading for any other interbank lending at UBS.

  • Bank of Canada's Carney says rate hikes will be gradual Thursday, 25 Oct 2012 | 4:00 AM ET

    OTTAWA, Oct 25- The Bank of Canada will take care not to raise interest rates too rapidly when the time comes because of risks to the economy from challenges in the United States and Europe, Governor Mark Carney said in an interview released on Thursday.

  • ADVISORY-UBS Singapore traders story withdrawn Thursday, 25 Oct 2012 | 3:59 AM ET

    Please be advised that a story saying UBS AG has suspended two traders in Singapore for possible manipulation of interbank lending rates is wrong and has been withdrawn. One of the traders named, Jeffrey Tay, said he had not been suspended but had resigned. STORYtNUMBER: L3E8LG35A STORYtDATE: 24/10/2012 STORYtTIME: 1240 GMT.

  • New drugs help maintain Novartis Q3 profit Thursday, 25 Oct 2012 | 3:56 AM ET

    GENEVA-- Swiss pharmaceutical giant Novartis AG posted flat third quarter profits as new drugs offset patent expirations.

  • *Q3 profits sink to $129 mln for Spain's Santander Thursday, 25 Oct 2012 | 3:54 AM ET
  • WPP says Olympics, US election income disappoints Thursday, 25 Oct 2012 | 3:50 AM ET

    LONDON-- WPP PLC, the world's largest advertising group, has lowered its full-year outlook after not doing as well as expected from the Olympics, the U.S. presidential campaign and the European soccer championships.

  • Credit Suisse to cut costs after Q3 profit slump Thursday, 25 Oct 2012 | 3:22 AM ET

    GENEVA-- Credit Suisse Group said Thursday it would boost its cost-cutting program as it posted a 63 percent fall in third-quarter profit following an accounting charge on its debt. Shares in Credit Suisse rose 2.3 percent to 21.82 francs in early trading on the Zurich exchange.

  • Sanofi earns slump in Q3 as competition heats up Thursday, 25 Oct 2012 | 2:59 AM ET

    PARIS-- Sanofi says earnings slumped in the third quarter as generic competitors ate into profits of its Eloxatin cancer treatment. Sanofi said it lost 448 million in sales from generic competition in the quarter. Overall sales rose 3.3 percent to 9 billion in the quarter, thanks in part to growth of Sanofi's Lantus diabetes treatment in the U.S.

  • Loss of exclusive drug dents AstraZeneca's Q3 Thursday, 25 Oct 2012 | 2:56 AM ET

    LONDON-- Anglo-Swedish pharmaceutical company AstraZeneca has reported a 56 percent drop in net income in the third quarter as it suffered from the loss of exclusivity on a big-selling drug. For the three months ending Sept. 30, AstraZeneca said Thursday that net profit fell to $1.5 billion compared to $3.5 billion a year earlier.